ArticleRheumatology (Oxford, England)2023
Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors.
Glen S HazlewoodPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it